Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women

Common Genetic Variants in the Myeloperoxidase and Paraoxonase Genes and the Related Cancer Risk: A Review

“…Furthermore, no protective effect was detected by Larsen and colleagues [23] in nonsmall cell lung cancer for either the GA or the AA genotype when compared to the wild-type GG genotype; protection was also not observed for carriers of Downloaded by [University of Windsor] at 23:08 20 November 2014 the A allele. Additionally, no statistically significant correlation between the rs2333227 SNP and lung cancer risk was observed in a series of studies conducted by Xu and associates [24], Salazar and associates [25], Chevrier and associates [26], Harms and associates [27], Skuladottir and associates [28], Park and associates [29], Yang and associates [30], Yoon associates [31], Zienolldiny and associates [32], and Klinchid and associates [33]. These studies were conducted utilizing Caucasian, Asian, and mixed populations.…”

hOGG1, p53 Genes, and Smoking Interactions are Associated with the Development of Lung Cancer

“…The risk of adenocarcinoma among people with p53 Pro genotype and GSTM1 null genotype is 1.80 (1.1-2.8) times high of that of squamous cancer, indicating that the interaction of p53 and GSTM1 can increase the subtype morbid risk of specific pathological types of non-small cell lung cancer. The polymorphism of p53 can increase lightly the risk of lung cancer among smokers with GSTM1 null genotype, and the OR (95% CI) of the interaction of GSTM1 absense and Pro/Pro or Arg/Pro is 1.97 (1.03 -3.73) compared to the interaction of GTSM1 and Arg/Arg genotypes (Klinchid et al, 2009).…”

Functional PstI/RsaI Polymorphisms in the CYP2E1 Gene among South Indian Populations

“…Two point mutations in the 5'-FR PstI and RsaI-which are in close linkage disequilibrium are known to generate the CYP2E1_1 (c1) allele and the less common CYP2E1_2 (c2) allele. PstI and RsaI have been associated with a greater risk for oral, pharyngeal (Matthias et al, 2002;Gattas et al, 2006), liver (Hata et al, 2010;Ye et al, 2010) and lung cancers (Klinchid et al, 2009;Wang et al, 2010). It is well established that frequencies of CYP2E1 polymorphisms differ markedly in among different ethnic and racial groups.…”

“…of crucial importance to the cancer development, a large number of studies have been carried out to investigate the association between the CYP2E1 polymorphisms and risk of various cancers, but findings have been inconsistent (Klinchid et al, 2009;Hata et al, 2010;Wang et al, 2010;Ye et al, 2010;Balaji et al, 2011;Sameer et al, 2011). Inhibition of CYP2E1 using tolfenamic acid attenuated the bioactivation of carcinogens potentially leading to the chemoprevention (Shukoor et al, 2012) and hence the development of effective CYP2E1 inhibitors, proved to be effective in preventing CYP2E1-mediated cancers.…”